USI - Email
Advanced molecular dynamics simulations for drug discovery
Host: Prof. Vittorio Limongelli
USI Lugano East Campus, room D5.01 // online
Cardiff University, UK
Drug discovery can nowadays rely on computational approaches, which can focus on specific drug binding sites and substrate-molecule interactions modes. While the molecular docking paradigm can provide some guidance in identifying and developing novel drugs, a complete mapping of the free energy of drug-substrate interaction is an emerging paradigm towards rational drug design. The free energy landscape paradigm allows for an explicit assessment of factors affecting interaction strength, including entropic contributions, which are essential to understand binding mode competition, as well as conformational degrees of freedom and the role of solvation. To exemplify this paradigm, we have focused on DNA secondary structure G-quadruplexes, which can control oncogene expression, and are therefore important targets in cancer research. The specific binding of gold carbene complexes to G4 was investigated by metadynamics, to assess drug-substrate bonding specificity and variety of binding poses. Metadynamics explores chemical processes along selected reaction coordinates, so-called collective variables (CV), efficiently achieving comprehensive scans of the totality of binding modes over the whole DNA G4 system. This makes for an overall unbiased mechanistic exploration of the system of interest, one that not only allows for a detailed investigation of binding mechanisms, but also includes the relative free energy ranking of all possible binding modes. Computationally, the strategy can be focused on identifying suitable CVs, which can drive the exploration of local conformational changes and global binding modes. This provides a simulation platform, which can be used to screen novel drugs, by testing their competition directly on the substrate, to identify the best candidate. Furthermore, the approach can be transferred to other systems, including membrane proteins, for a complete reconnaissance of mechanisms underlying small molecule drug transport and their action.
Stefano Leoni - Dipl. Chem. ETH (B.Sc.), Eidgenössische Technische Hochschule (ETH), Zürich (1993), PhD ETH Zürich (1998). Postdoctoral Fellow, ETH Zürich (1999-2000), Max-Planck Society Postdoctoral Scholarship, Max-Planck Institute CPfS, Dresden (2000-2003), Advanced Research Fellow of the Swiss National Foundation (2004-2006), Research group leader & Lecturer, MPI Dresden and Dresden University of Technology (2006-2010), Habilitation, MPI & Department of Chemistry, Dresden (2009), Senior researcher & group leader, Dresden (2010-2013), Distinguished DFG Heisenberg Fellow (2013).
INF Newsletter Archive